Cancer & Genome Analysis

The use of genetic information plays a crucial role in precision medicine.
It not only detects cancer, but can also figure out or susceptibility,
if it will show a good prognosis, or verify the causes of relapse.
Identifying the genomic information of cancer contributes to higher treatment success rate.

We are more focused on -

Liquid Biopsy-based Cancer Genome Analysis

DNA which comes into blood vessels directly from various cells that compose cancer is called circulating tumor DNA (ctDNA), and analyzing this enables directly monitoring tumor dynamics.
Because ctDNA takes up a small portion of normal DNA, however, it is difficult to monitor the changes in the cancer genome which transforms in blood.

Cancer to Chronic Disease

Sampling with blood is less demanding to patients and so can be conducted regularly, and setting a direction for
treatment through regularly analyzing blood genome allows cancer to turn into a chronic disease.

Immune Checkpoint Inhibitor

Cancer cell confuses the immune checkpoint protein on the surface of immune cell (T cell) to avoid the attack by the immune cell. When
the immune checkpoint inhibitor interferes with the coupling of such cancer cell and immune checkpoint protein, the immune cell attacks
and removes the cancer cell. The clinical research has been actively carried out to find the biomarker to select the patient suitable for the
use of immune checkpoint inhibitor. Recently, such research result has been presented that the condition of microsatellite is highly related
to the effect of immune checkpoint inhibitor.

Microsatellite

Microsatellite is a part where the short sequencing repeats several
times among entire human genes. Microsatellite is a vulnerable
part for gene replication error, which has been used for the
biomarker of test on the abnormality of gene repair system.

If mismatch repair gene does not function properly, the number of repeats of microsatellite cannot be maintained constantly
but abnormally increased or decreased. Such condition is called
'Microsatellite Instability (MSI).

Microsatellite Instability - Response to Immunotherapy

Microsatellite instability, MSI

Microsatellite instability is a type generated by the problem of the
system that repairs the problem (mismatch) occurred during the
replication of DNA. If mismatch repair system does not function
properly, the number of repeats of microsatellite cannot be
maintained constantly, but abnormally increased or decreased.
Such condition is called 'Microsatellite Instability (MSI).

The condition of microsatellite has been traditionally used for the
classification of colon cancer. Since the result was presented for
the high treatment efficiency by immune checkpoint inhibitor on
the metastatic colon cancer which is the microsatellite instability,
recently the microsatellite instability has been used in various
cancers for the useful marker of the prescription of specific
immune checkpoint inhibitor (Pembrolizumab, etc).

Comparison of colon cancer patients' survival rates
A clinical research shows that patients with MSI colon cancer
register a good prognosis for treatment with immune checkpoint
inhibitor (Pembrolizumab, PD-1 blockade) than those with MSS
(microsatellite stability) colon cancer. (Le et al., 2015. N Engl J
Med.)

Diagnosing Microsatellite instability

Microsatellite instability (MSI) has been used for the marker to show the condition of cancer. In general, it is classified to MSI-H, MSI-L and
MSS. More than 2 genes of MSI-H are in unstable condition among 5 genes of microsatellite. One gene of MSI-L is in unstable condition among 5 genes of microsatellite. It is called MSS when all 5 genes of microsatellite are in stable condition. Generally, the method to diagnose the instability of microsatellite genes uses the fragment analysis after PCR
MSI Detection Kit
The instability diagnosis on microsatellite based on the real time polymerase chain reaction is analyzed for the result analysis through one
step. The analysis is carried out by converting the difference of gene length between normal tissue and cancer tissue to the difference of temperature.
Related Product

Our technologies

MeltingArray
Real-time PCR base diagnosis platform technology
for the change in gene length
MeltingArray is the real-time PCR base diagnosis
technology that amplifies the gene of different
length from that of normal gene but also carries
out the fluorescence analysis.
Insight Onco
Next generation sequencing analysis base
high sensitive genome analysis platform technology
Insight™ Onco is the genome analysis
technology based on the next generation
sequencing analysis that amplifies to analyze the
gene mutation in relation to the cancer existed in low rate.
* Ins: Insertion
* Del: Deletion
MeltingArray is the technology that converts the length change of normal gene to the
temperature change.

* Green color: Analysis result of normal tissue/Other color: Analysis result of cancer tissue

Analyzing the gene extracted from normal tissue and the gene extracted from cancer
tissue with MeltingArray to compare the temperature difference, it is available to test the
gene mutation of tissue.

Insight Onco (Highly Sensitive Genome Analysis)

With mutant enrichment technologies, we were able to detect cancer related mutations at minimum frequencies of 0.05%.
Highly sensitive genomic analysis platform is a technology that can advance treatment
by conducting an early analysis of mutation in blood.